Literature DB >> 16306063

Common pathological mechanisms in mouse models for muscular dystrophies.

R Turk1, E Sterrenburg, C G C van der Wees, E J de Meijer, R X de Menezes, S Groh, K P Campbell, S Noguchi, G J B van Ommen, J T den Dunnen, P A C 't Hoen.   

Abstract

Duchenne/Becker and limb-girdle muscular dystrophies share clinical symptoms like muscle weakness and wasting but differ in clinical presentation and severity. To get a closer view on the differentiating molecular events responsible for the muscular dystrophies, we have carried out a comparative gene expression profiling of hindlimb muscles of the following mouse models: dystrophin-deficient (mdx, mdx(3cv)), sarcoglycan-deficient (Sgca null, Sgcb null, Sgcg null, Sgcd null), dysferlin-deficient (Dysf null, SJL(Dysf)), sarcospan-deficient (Sspn null), and wild-type (C57Bl/6, C57Bl/10) mice. The expression profiles clearly discriminated between severely affected (dystrophinopathies and sarcoglycanopathies) and mildly or nonaffected models (dysferlinopathies, sarcospan-deficiency, wild-type). Dystrophin-deficient and sarcoglycan-deficient profiles were remarkably similar, sharing inflammatory and structural remodeling processes. These processes were also ongoing in dysferlin-deficient animals, albeit at lower levels, in agreement with the later age of onset of this muscular dystrophy. The inflammatory proteins Spp1 and S100a9 were up-regulated in all models, including sarcospan-deficient mice, which points, for the first time, at a subtle phenotype for Sspn null mice. In conclusion, we identified biomarker genes for which expression correlates with the severity of the disease, which can be used for monitoring disease progression. This comparative study is an integrating step toward the development of an expression profiling-based diagnostic approach for muscular dystrophies in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306063     DOI: 10.1096/fj.05-4678fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  37 in total

1.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

2.  Over-expression of Microspan, a novel component of the sarcoplasmic reticulum, causes severe muscle pathology with triad abnormalities.

Authors:  Gaynor Miller; Angela K Peter; Erica Espinoza; Jim Heighway; Rachelle H Crosbie
Journal:  J Muscle Res Cell Motil       Date:  2006-07-04       Impact factor: 2.698

3.  Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle.

Authors:  Sanjeewa A Goonasekera; Chi K Lam; Douglas P Millay; Michelle A Sargent; Roger J Hajjar; Evangelia G Kranias; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2011-03       Impact factor: 14.808

4.  Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle.

Authors:  Aurelia Defour; Sushma Medikayala; Jack H Van der Meulen; Marshall W Hogarth; Nicholas Holdreith; Apostolos Malatras; William Duddy; Jessica Boehler; Kanneboyina Nagaraju; Jyoti K Jaiswal
Journal:  Hum Mol Genet       Date:  2017-06-01       Impact factor: 6.150

5.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.

Authors:  E Pegoraro; E P Hoffman; L Piva; B F Gavassini; S Cagnin; M Ermani; L Bello; G Soraru; B Pacchioni; M D Bonifati; G Lanfranchi; C Angelini; A Kesari; I Lee; H Gordish-Dressman; J M Devaney; C M McDonald
Journal:  Neurology       Date:  2010-12-22       Impact factor: 9.910

Review 6.  Outside in: The matrix as a modifier of muscular dystrophy.

Authors:  Mattia Quattrocelli; Melissa J Spencer; Elizabeth M McNally
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-12-21       Impact factor: 4.739

7.  Tissue-specific transcript annotation and expression profiling with complementary next-generation sequencing technologies.

Authors:  Matthew S Hestand; Andreas Klingenhoff; Matthias Scherf; Yavuz Ariyurek; Yolande Ramos; Wilbert van Workum; Makoto Suzuki; Thomas Werner; Gert-Jan B van Ommen; Johan T den Dunnen; Matthias Harbers; Peter A C 't Hoen
Journal:  Nucleic Acids Res       Date:  2010-07-07       Impact factor: 16.971

8.  Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation, and increased expression of extracellular matrix proteins in laminin α2 chain-deficient muscle.

Authors:  Bruno Menezes de Oliveira; Cintia Y Matsumura; Cibely C Fontes-Oliveira; Kinga I Gawlik; Helena Acosta; Patrik Wernhoff; Madeleine Durbeej
Journal:  Mol Cell Proteomics       Date:  2014-07-03       Impact factor: 5.911

9.  The Dietary Supplement Protandim Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice.

Authors:  Muhammad Muddasir Qureshi; Warren C McClure; Nicole L Arevalo; Rick E Rabon; Benjamin Mohr; Swapan K Bose; Joe M McCord; Brian S Tseng
Journal:  J Diet Suppl       Date:  2010-06-01

Review 10.  Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Miranda D Grounds; Hannah G Radley; Gordon S Lynch; Kanneboyina Nagaraju; Annamaria De Luca
Journal:  Neurobiol Dis       Date:  2008-04-09       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.